EDE clears AstraZeneca Etcamah after 55% PFS risk cut, ahead of FDA decision

Emirates Drug Establishment (EDE) approved AstraZeneca’s Etcamah after SERENA-6 linked the switch strategy to a 55% lower risk of first progression or death.

The decision gives UAE medical directors and CFOs a near-term question in 2026: whether advanced breast cancer pathways should pay for repeat ESR1 testing before CT or MRI evidence of progression.

What EDE approved

EDE approved Etcamah for adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer whose tumours develop an ESR1 mutation during endocrine treatment, according to Khaleej Times. The active ingredient is camizestrant, an oral selective estrogen receptor degrader.

AstraZeneca said Etcamah is used with a CDK4/6 inhibitor, the same class as palbociclib, ribociclib and abemaciclib. In SERENA-6, the company reported median progression-free survival of 16.8 months for camizestrant plus a CDK4/6 inhibitor, compared with 9.2 months for continued aromatase inhibitor therapy plus a CDK4/6 inhibitor.

AstraZeneca said the regimen reduced the risk of first progression or death by 55% and the risk of second progression or death by 37%. For oncology committees, the number to remember is the 7.6-month median progression-free survival difference.

What hospitals and payers must decide

The approval moves ESR1 testing into pathway design for UAE cancer centres. Medical directors will need to specify which patients receive circulating tumour DNA testing, how often testing is repeated and whether a positive ESR1 result triggers a switch before radiographic progression.

For COOs, the implementation work sits across tumour boards, laboratory contracts and pharmacy governance. A practical checklist has 4 decisions:

• Define the eligible population: HR-positive, HER2-negative advanced or metastatic breast cancer on first-line endocrine therapy plus a CDK4/6 inhibitor.
• Set an ESR1 testing interval and decide whether testing uses an in-house lab or a reference-lab liquid biopsy.
• Update oncology pharmacy protocols for oral adherence checks, drug interaction review and adverse-event documentation.
• Prepare insurer submissions with SERENA-6 endpoints, testing costs and expected treatment duration.

The payer issue is immediate because oral targeted therapies move spending into outpatient pharmacy budgets and repeat molecular testing adds a separate cost line. CFOs should model Etcamah and serial liquid biopsy together, rather than treating the drug as a single formulary addition.

Regulatory context for UAE providers

EDE is the federal medicines regulator for this approval. Care delivery remains split by emirate: the Dubai Health Authority (DHA) regulates Dubai facilities, the Department of Health Abu Dhabi (DOH) regulates Abu Dhabi and Al Ain, and the Ministry of Health and Prevention (MOHAP) oversees the Northern Emirates healthcare system.

That split matters because a federal drug approval does not standardise prescribing protocols, prior authorisation rules or laboratory contracting across 7 emirates. Providers operating in Dubai, Abu Dhabi and Sharjah will need local pathway alignment with DHA, DOH and MOHAP-licensed settings.

The Global Cancer Observatory estimated 1,142 new female breast cancer cases in the UAE in 2022, equal to 39.1% of new female cancer cases. The same dataset ranked breast cancer as the country’s leading cancer among women.

The UAE approval comes before a final US decision. The FDA’s Oncologic Drugs Advisory Committee voted 6-3 on 30 April 2026 that the benefit-risk assessment was not favourable for camizestrant in this setting, while the European Medicines Agency said its CHMP adopted a positive opinion for Etcamah on 21 May 2026.

UAE operators should watch 2 signals during 2026: whether insurers reimburse serial ESR1 testing, and whether DHA and DOH oncology pathways reference the EDE approval. Those decisions will determine whether Etcamah becomes a routine switch strategy or remains limited to centres that can absorb testing and pharmacy complexity.